-
Korean prostate cancer radiopharmaceutical dosed 1st US patient in P2 trial
13 May 2024 08:17 GMT
… s FC705 is a prostate cancer treatment developed using a best … uptake than competitive drugs while minimizing side effects … the drug in patients with castration-resistant metastatic prostate cancer.
… "The Korean phase 2 clinical trial …
-
StockWatch: MacroGenics Shares Crater after Trial Deaths
12 May 2024 14:29 GMT
… Phase II TAMARACK trial (NCT05551117) assessing its antibody-drug conjugate (ADC) … prostate cancer.
The company said it continues to investigate the potentially treatment … Phase IIa trial (NCT05935332) assessing zelnecirnon in asthma. The FDA placed …
-
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
10 May 2024 19:16 GMT
… prostate cancer (mCRPC).
MacroGenics reported five deaths (fatal outcome) during the trial … an unexpected increase in treatment interruptions and discontinuations from … landscape in metastatic castration-resistant prostate cancer (mCRPC) and the standards …
-
Five Deaths in Prostate Cancer Trial Send MacroGenics’ Stock Plummeting
10 May 2024 16:49 GMT
… II TAMARACK trial for its investigational antibody-drug conjugate vobramitamab … duocarmazine in metastatic castration-resistant prostate cancer.
The … counting even unconfirmed instances of treatment response. At the higher …
-
MacroGenics investigates three patient deaths in Phase 2 prostate cancer drug trial
10 May 2024 12:19 GMT
… a mid-stage trial of its antibody-drug conjugate for prostate cancer. Two participants … five patients died in the trial, although two of the deaths … one patient in the trial had a treatment-emergent adverse event and …
-
Fusion Pharmaceuticals doses first subject in prostate cancer trial
10 May 2024 12:19 GMT
… treat metastatic castration-resistant prostate cancer (mCRPC).
The open-label, randomised, multicentre AlphaBreak trial … US Food and Drug Administration to … tissue.
Fusion Pharmaceuticals chief medical officer … important potential new treatment option for …
-
Exposed: The black market dealers selling puberty blocker drugs to British teenagers who are cheating ban
11 May 2024 21:48 GMT
… drugs from three different websites in recent weeks.
The online pharmacies … Turkey, shipped a testosterone-blocking drug called bicalutamide from Istanbul. … a prescription-only medication usually used for treating prostate cancer.
But influencers posting …
-
Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer
10 May 2024 04:49 GMT
… metastatic castration-resistant prostate cancer (mCRPC).
… Drug Administration (FDA), the Phase 3 global registration portion of the AlphaBreak trial … in cancer treatment. By delivering … Communications
SOURCE Fusion Pharmaceuticals
Copyright © 2024 …
-
Diffuse Pneumonitis after Lutetium-177-PSMA-617 Treatment in a Patient with Metastatic Castration-Resistant Prostate Cancer - Beyond the Abstract
09 May 2024 20:52 GMT
We present the case of a patient with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) who underwent treatment with lutetium Lu-177 vipivotide tetraxetan (also known as 177Lu-PSMA-617) due to progressive disease despite multiple …
-
Moving Treatments Earlier in Prostate Cancer Can Prevent Progression, Additional Treatment
09 May 2024 19:12 GMT
… on treatment sequencing and survival of localized or locally advanced prostate cancer in … treatments and the burden of subsequent treatments for localized or locally advanced prostate cancer … idea is, if we can treat them early and aggressively and …